The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus
(2021) In Informatics in medicine unlocked 23.- Abstract
Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease. Because of that we analyzed the inhibition of SARS-CoV-2 spike glycoprotein with FDA-approved antiviral drugs and their double and triple combinations. We used the VINI in silico model of cancer to perform this virtual drug screening, showing HIV drugs to be the most effective. Besides, the combination of cobicistat-abacavir-rilpivirine HIV drugs demonstrated the highest in silico efficacy of inhibiting SARS-CoV-2 spike glycoprotein. Therefore, a clinical trial of cobicistat-abacavir-rilpivirine on a limited number of COVID-19... (More)
Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease. Because of that we analyzed the inhibition of SARS-CoV-2 spike glycoprotein with FDA-approved antiviral drugs and their double and triple combinations. We used the VINI in silico model of cancer to perform this virtual drug screening, showing HIV drugs to be the most effective. Besides, the combination of cobicistat-abacavir-rilpivirine HIV drugs demonstrated the highest in silico efficacy of inhibiting SARS-CoV-2 spike glycoprotein. Therefore, a clinical trial of cobicistat-abacavir-rilpivirine on a limited number of COVID-19 patients in moderately severe and severe condition is warranted.
(Less)
- author
- organization
- publishing date
- 2021-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Antiviral drugs, COVID-19, HIV cocktail Therapy, Inhibition efficiency, SARS-CoV-2 spike glycoprotein, Virtual drug screening
- in
- Informatics in medicine unlocked
- volume
- 23
- article number
- 100529
- publisher
- Elsevier
- external identifiers
-
- scopus:85103721514
- pmid:33553571
- ISSN
- 2352-9148
- DOI
- 10.1016/j.imu.2021.100529
- language
- English
- LU publication?
- yes
- id
- 4fc2c9ce-b2f5-451e-9f43-34abcb3520c9
- date added to LUP
- 2021-12-23 11:53:48
- date last changed
- 2024-07-28 03:35:36
@article{4fc2c9ce-b2f5-451e-9f43-34abcb3520c9, abstract = {{<p>Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease. Because of that we analyzed the inhibition of SARS-CoV-2 spike glycoprotein with FDA-approved antiviral drugs and their double and triple combinations. We used the VINI in silico model of cancer to perform this virtual drug screening, showing HIV drugs to be the most effective. Besides, the combination of cobicistat-abacavir-rilpivirine HIV drugs demonstrated the highest in silico efficacy of inhibiting SARS-CoV-2 spike glycoprotein. Therefore, a clinical trial of cobicistat-abacavir-rilpivirine on a limited number of COVID-19 patients in moderately severe and severe condition is warranted.</p>}}, author = {{Tomić, Draško and Davidović, Davor and Szasz, Attila Marcel and Rezeli, Melinda and Pirkić, Boris and Petrik, Jozsef and Vrca, Vesna Bačić and Janđel, Vladimir and Lipić, Tomislav and Skala, Karolj and Mesarić, Josip and Periša, Marija Milković and Šojat, Zorislav and Rogina, Branka Medved}}, issn = {{2352-9148}}, keywords = {{Antiviral drugs; COVID-19; HIV cocktail Therapy; Inhibition efficiency; SARS-CoV-2 spike glycoprotein; Virtual drug screening}}, language = {{eng}}, publisher = {{Elsevier}}, series = {{Informatics in medicine unlocked}}, title = {{The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus}}, url = {{http://dx.doi.org/10.1016/j.imu.2021.100529}}, doi = {{10.1016/j.imu.2021.100529}}, volume = {{23}}, year = {{2021}}, }